Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

You may not qualify if:

• Prior courses of TSEBT (Note : localized skin-directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study).
• Concomitant use of any anti-cancer therapy or immune modifier.
• Receiving colony stimulating factors.
• Prior allogeneic or autologous transplant.
• Active infection or have received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug.
• Known history of human immunodeficiency virus (HIV), hepatitis B or C.
• History of prior malignancy with the exception of cervical intraepithelial neoplasia, non-melanoma skin cancer, and adequately treated localized prostate carcinoma (PSA \< 1.0). Patients with a history of other malignancies must have undergone potentially curative therapy and have no evidence of that disease for 5 years.
• Uncontrolled intercurrent illness, condition, or circumstances that could limit compliance with the study, including, but not limited to the following: active infection, acute or chronic graft versus host disease, symptomatic congestive heart failure, unstable angina pectoris, medically significant cardiac arrhythmia, uncontrolled diabetes mellitus or hypertension, or psychiatric conditions.
• Medically significant cardiac event in prior 6 months (ie, myocardial infarction, cardiac surgery.
• Congenital long QT syndrome.
• QTc interval \> 480 msec on screening ECG.
• Proven or suspected stage IV disease including patients with B2 (Sezary syndrome); N3 (frank LN disease); or M1 (visceral disease) categories; presence of reactive or dermatopathic lymphadenopathy (N1-2) or limited blood involvement (B1) is permitted.
• Pregnant or lactating.
• Unwilling to use reliable birth control methods.
• Any other medical issue, including laboratory abnormalities, deemed by the Investigator to be likely to interfere with patient participation.
• +1 more criteria